Determination of α-1 Acid Glycoprotein in Patients with Ph+ Chronic Myeloid Leukemia during the First 13 Weeks of Therapy with STI571
- 1 January 2002
- journal article
- Published by Elsevier in Blood Cells, Molecules, and Diseases
- Vol. 28 (1) , 75-85
- https://doi.org/10.1006/bcmd.2002.0493
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Roots of Clinical Resistance to STI-571 Cancer TherapyScience, 2001
- Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or AmplificationScience, 2001
- Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia ChromosomeNew England Journal of Medicine, 2001
- Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid LeukemiaNew England Journal of Medicine, 2001
- Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistanceBlood, 2000
- Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL–transformed hematopoietic cell linesBlood, 2000
- Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplificationBlood, 2000
- In Vivo Eradication of Human BCR/ABL-Positive Leukemia Cells With an ABL Kinase InhibitorJNCI Journal of the National Cancer Institute, 1999
- Inhibition of the ABL Kinase Activity Blocks the Proliferation of BCR/ABL+Leukemic Cells and Induces ApoptosisBlood Cells, Molecules, and Diseases, 1997
- Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cellsNature Medicine, 1996